Investors in the cell therapy industry are actively looking into solid tumours, autoimmune indications and novel engineering as the best place to allocate their money and resources.
Implement State-of-the-Art, Reproducible & Predictive in vivo & in vitro Oncology Models to Successfully Identify Promising Targets & Biomarkers, & Surmount the Translationa
Following Merck announcing their goal to phase out animal use in their work, Astellas and MIMETAS expanding their partnership in immunotherapeutic development, and the domino effects across the fie
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl